-Trinity Biotech projects it reached Adjusted EBITDA -positive operations during Q2 2025 and expects to be Adjusted EBITDA positive going forward, reflecting continued strong execution on its comprehensive transformation plan.- - The Company now expects to be meaningfully Adjusted EBITDA -positive and cashflow positive from ongoing operating activities, starting Q3 2025 and into the foreseeable future.- DUBLIN, July 01, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechn ...